XML 72 R55.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenue - Jansen Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2021 | Dec. 31, 2020 | May 31, 2020 | Dec. 31, 2022 | Dec. 31, 2021
Research and license agreement |  |  |  |  |
Revenue |  |  |  |  |
Development milestones payment received | $ 1,000 |  |  |  |
Janssen Biotech Inc |  |  |  |  |
Revenue |  |  |  |  |
Deferred revenue at beginning of period |  |  |  | $ (1,527) | $ (6,176)
Deferral of revenue |  |  |  | (35,000) |
Recognized during the period |  |  |  | 1,490 | 4,354
Foreign currency translation difference |  |  |  | 37 | 295
Deferred revenue at end of period |  | $ (6,176) |  | $ (35,000) | $ (1,527)
Development milestones payment received |  | $ 1,000 |  |  |
Janssen Biotech Inc | Research and license agreement |  |  |  |  |
Revenue |  |  |  |  |
Non-refundable upfront payment received |  |  | $ 8,000 |  |
Term of agreement |  |  | 2 years |  |
Years of sale for royalties payable |  |  |  | 10 years |
Deferred revenue at end of period |  |  |  | $ 0 |

X
- Definition The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 105 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 116 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in contract liabilities resulting from cumulative catch-up adjustments to revenue. [Refer: Contract liabilities; Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 15 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118_b&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in contract liabilities resulting from foreign currency translation difference. + References No definition available. + Details
Name: | lvtx_IncreaseDecreaseThroughForeignCurrencyTranslationDifferenceContractLiabilities
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development milestones payment received under research and license agreement. + References No definition available. + Details
Name: | lvtx_ResearchAndLicenseAgreementDevelopmentMilestonesPaymentReceived
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable upfront payment received under research and license agreement. + References No definition available. + Details
Name: | lvtx_ResearchAndLicenseAgreementNonRefundableUpfrontPaymentReceived
Namespace Prefix: | lvtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Years of sale for royalties payable under research and license agreement. + References No definition available. + Details
Name: | lvtx_ResearchAndLicenseAgreementRoyaltiesPayableYearsOfSale
Namespace Prefix: | lvtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of agreement over which upfront payment received are recognized on a straight-line basis. + References No definition available. + Details
Name: | lvtx_TermOfResearchAndLicenseAgreement
Namespace Prefix: | lvtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | lvtx_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=lvtx_ResearchAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=lvtx_JanssenBiotechincMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |